List of Biologic & Biosimilar Drugs

Click on the names below to read more about each medication.

List of Biologics and Biosimilars (Psoriasis)

List of Biologics and Biosimilars (Psoriatic Arthritis)

Etanercept (TNF Blocker)

How Does It Work?

Etanercept is a biologic that targets the overactive immune system in psoriasis. Etanercept works by supressing tumor necrosis factor-alpha (TNFa). Useful in psoriasis and psoriatic arthritis.

How Is It Used?

Etanercept is an injectable medication that is administered subcutaneously. This can be home dosed.

For plaque psoriasis:
50 mg twice weekly for 3 months, then 50 mg once weekly thereafter

For psoriatic arthritis:
50 mg once weekly

What Are The Possible Side Effects?

The most common side effects of etanercept include temporary pain and redness around the injection site, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of etanercept, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on etanercept. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on etanercept.

Etanercept and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Etanercept should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

Etanercept should be avoided in patients who are immunocompromised or HIV positive.

What Medications Interact With This Treatment?

Some medications that may interact with etanercept include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with etanercept and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Province	Class	Generic Name	Drug Name	Psoriasis	Psoriatic Arthritis
Alberta	Biologics and Biosimilars	Etanercept	Enbrel®	No	No
Alberta	Biologics and Biosimilars	Etanercept	Erelzi™	Yes – S/A	Yes – S/A
Alberta	Biologics and Biosimilars	Etanercept	Brenzys®	Yes – S/A	Yes – S/A
Alberta	Biologics and Biosimilars	Etanercept	Rymti	Yes - S/A	Yes - S/A
British Columbia	Biologics and Biosimilars	etanercept	Enbrel®	No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.	No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.
British Columbia	Biologics and Biosimilars	Etanercept	Erelzi™	Yes - S/A	Yes – S/A
British Columbia	Biologics and Biosimilars	Etanercept	Brenzys®	Yes - S/A	Yes – S/A
Manitoba	Biologics and Biosimilars	Etanercept	Enbrel®	Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriasis.	Yes – EDS. Erelzi or Brenzys will be the preferred etanercept option for all etanercept-naïve patients prescribed an etanercept product for psoriatic arthritis.
Manitoba	Biologics and Biosimilars	Etanercept	Erelzi™	Yes – EDS	Yes – EDS
Manitoba	Biologics and Biosimilars	Etanercept	Brenzys®	Yes - EDS	Yes - EDS
New Brunswick	Biologics and Biosimilars	Etanercept	Enbrel®	No	No
New Brunswick	Biologics and Biosimilars	Etanercept	Erelzi™	Yes – S/A	Yes – S/A
New Brunswick	Biologics and Biosimilars	Etanercept	Brenzys®	Yes - S/A	Yes - S/A
New Brunswick	Biologics and Biosimilars	Etanercept	Rymti	Yes – S/A	Yes – S/A
Newfoundland and Labrador	Biologics and Biosimilars	Etanercept	Enbrel®	No	No
Newfoundland and Labrador	Biologics and Biosimilars	Etanercept	Erelzi™	Yes – S/A	Yes – S/A
Newfoundland and Labrador	Biologics and Biosimilars	Etanercept	Brenzys®	Yes – S/A	Yes – S/A
NIHB	Biologics and Biosimilars	Etanercept	Enbrel®	No	Yes- Only for clients who received approval for Enbrel before October 2, 2017
NIHB	Biologics and Biosimilars	Etanercept	Erelzi™	No	Yes- L/U
NIHB	Biologics and Biosimilars	Etanercept	Brenzys®	No	Yes - L/U
NIHB	Biologics and Biosimilars	Etanercept	Rymti	No	Yes - L/U
Northwest Territories	Biologics and Biosimilars	Etanercept	Enbrel®	No	Yes – L/U
Northwest Territories	Biologics and Biosimilars	Etanercept	Erelzi™	Yes- L/U	Yes – L/U
Northwest Territories	Biologics and Biosimilars	Etanercept	Brenzys®	No	Yes - L/U
Northwest Territories	Biologics and Biosimilars	Etanercept	Rymti	No	Yes - L/U
Nova Scotia	Biologics and Biosimilars	Etanercept	Enbrel®	Yes – EDS; for etanercept-naïve patients whose etanercept therapy is initiated after Nov 1, 2017, a biosimilar will be the product that is approved.	Yes – EDS; for etanercept-naïve patients whose etanercept therapy is initiated after Nov 1, 2017, a biosimilar will be the product that is approved.
Nova Scotia	Biologics and Biosimilars	Etanercept	Erelzi™	No	Yes – EDS
Nova Scotia	Biologics and Biosimilars	Etanercept	Brenzys®	Yes - EDS	Yes - EDS
Nova Scotia	Biologics and Biosimilars	Etanercept	Rymti	Yes - EDS	Yes - EDS
Nunavut	Biologics and Biosimilars	Etanercept	Brenzys®	No	Yes - L/U
Nunavut	Biologics and Biosimilars	Etanercept	Enbrel®	No	Yes – L/U
Nunavut	Biologics and Biosimilars	Etanercept	Erelzi™	Yes- L/U	Yes – L/U
Ontario	Biologics and Biosimilars	Etanercept	Brenzys®	Yes – L/U	Yes – L/U
Ontario	Biologics and Biosimilars	Etanercept	Enbrel®	Yes - EAP	Yes - EAP
Ontario	Biologics and Biosimilars	Etanercept	Erelzi™	Yes – L/U	Yes – L/U
Ontario	Biologics and Biosimilars	Etanercept	Rymti	Yes - L/U	Yes - L/U
Prince Edward Island	Biologics and Biosimilars	Etanercept	Enbrel®	Yes – S/A	Yes – S/A
Prince Edward Island	Biologics and Biosimilars	Etanercept	Erelzi™	Yes – S/A	Yes – S/A
Prince Edward Island	Biologics and Biosimilars	Etanercept	Brenzys®	Yes – S/A	Yes – S/A
Quebec	Biologics and Biosimilars	Etanercept	Enbrel®	Yes – S/A. If treatment began before August 19, 2020	Yes – S/A. If treatment began before August 19, 2020
Quebec	Biologics and Biosimilars	Etanercept	Erelzi™	Yes – S/A	Yes – S/A
Quebec	Biologics and Biosimilars	Etanercept	Brenzys®	Yes – S/A	Yes – S/A
Quebec	Biologics and Biosimilars	Etanercept	Rymti	Yes – S/A	Yes – S/A
Saskatchewan	Biologics and Biosimilars	Etanercept	Enbrel®	No	No
Saskatchewan	Biologics and Biosimilars	Etanercept	Erelzi™	Yes – EDS	Yes – EDS
Saskatchewan	Biologics and Biosimilars	Etanercept	Brenzys®	Yes – EDS	Yes – EDS
Yukon	Biologics and Biosimilars	Etanercept	Enbrel®	Yes - EDS ; all new etanercept patients will be covered for Brenzys or Erelzi	Yes – EDS; all new etanercept patients will be covered for Erelzi
Yukon	Biologics and Biosimilars	Etanercept	Erelzi™	Yes - EDS	Yes – EDS
Yukon	Biologics and Biosimilars	Etanercept	Brenzys®	Yes - EDS	Yes – EDS
Nunavut	Biologics and Biosimilars	Etanercept	Rymti	No	Yes - L/U

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

Brenzys®: https://pdf.hres.ca/dpd_pm/00065129.PDF
Enbrel®: https://pdf.hres.ca/dpd_pm/00060454.PDF
Erelzi™: https://pdf.hres.ca/dpd_pm/00069556.PDF
Rymti: https://pdf.hres.ca/dpd_pm/00068678.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Etanercept (Enbrel^®): https://www.amgen.ca/products/patient-assistance/
Etanercept biosimilar (Erelzi^™): Call 1-844-27XPOSE (1-844-279-7673) for information

Brenzys
Harmony patient support program
Phone 1-866-556-5663
https://rheuminfo.com/docs/physician-tools/patient-support-programs/Brenzys_EN.pdf

↑ Back to list of biologics and biosimilars

Adalimumab (TNF Blocker)

How Does It Work?

Adalimumab is a biologic that targets the overactive immune system in psoriasis. Adalimumab works by supressing tumor necrosis factor (TNFa). Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Adalimumab is an injectable medication that is administered subcutaneously. This can be home dosed.

For plaque psoriasis:
80 mg as an initial dose, then 40 mg every other week starting one week after initial dose

For psoriatic arthritis:
40 mg every other week

What Are The Possible Side Effects?

The most common side effects of adalimumab include temporary pain and redness around the injection site, headaches, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of adalimumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on adalimumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on adalimumab.

Adalimumab and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Adalimumab should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with adalimumab include abatacept (Orencia®), anakinra (Kineret®) and other TNF-blockers such as Enbrel®, Remicade®, Cimzia®, or Simponi®. Adalimumab can potentially affect the speed at which cyclosporine and warfarin are metabolized and their doses may need to be adjusted. For a complete list of medications that may interact with adalimumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Province	Class	Generic Name	Drug Name	Psoriasis	Psoriatic Arthritis
Alberta	Biologics and Biosimilars	Adalimumab	Humira®	No	No
Alberta	Biologics and Biosimilars	Adalimumab	Hadlima®	Yes - S/A	Yes - S/A
Alberta	Biologics and Biosimilars	Adalimumab	Hyrimoz®	Yes - S/A	Yes - S/A
Alberta	Biologics and Biosimilars	Adalimumab	Idacio®	Yes - S/A	Yes - S/A
Alberta	Biologics and Biosimilars	Adalimumab	Amgevita®	Yes - S/A	Yes - S/A
Alberta	Biologics and Biosimilars	Adalimumab	Hulio®	Yes - S/A	Yes - S/A
Alberta	Biologics and Biosimilars	Adalimumab	Abrilada	Yes – S/A	Yes – S/A
Alberta	Biologics and Biosimilars	Adalimumab	Simlandi	Yes – S/A	Yes – S/A
Alberta	Biologics and Biosimilars	Adalimumab	Yuflyma	Yes – S/A	Yes – S/A
British Columbia	Biologics and Biosimilars	Adalimumab	Humira®	No – S/A requests for psoriasis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.	No – S/A requests for psoriatic arthritis patients who are unable to transition to biosimilar could be considered on an exceptional case-by-case basis.
British Columbia	Biologics and Biosimilars	Adalimumab	Hadlima®	Yes - S/A	Yes - S/A
British Columbia	Biologics and Biosimilars	Adalimumab	Hyrimoz®	Yes - S/A	Yes - S/A
British Columbia	Biologics and Biosimilars	Adalimumab	Idacio®	Yes - S/A	Yes - S/A
British Columbia	Biologics and Biosimilars	Adalimumab	Amgevita®	Yes - S/A	Yes - S/A
British Columbia	Biologics and Biosimilars	Adalimumab	Hulio®	Yes - S/A	Yes - S/A
British Columbia	Biologics and Biosimilars	Adalimumab	Abrilada	Yes - S/A	Yes - S/A
British Columbia	Biologics and Biosimilars	Adalimumab	Simlandi	Yes - S/A	Yes - S/A
British Columbia	Biologics and Biosimilars	Adalimumab	Yuflyma	Yes - S/A	Yes - S/A
Manitoba	Biologics and Biosimilars	Adalimumab	Humira®	Yes - EDS. Hadlima, Hyrimoz, Idacio, Amgevita or Idacio will be the preferred adalimumab option for all adalimumab-naïve patients prescribed an adalimumab product for psoriasis.	Yes - EDS. Hadlima, Hyrimoz, Idacio, Amgevita or Idacio will be the preferred adalimumab option for all adalimumab-naïve patients prescribed an adalimumab product for psoriatic arthritis.
Manitoba	Biologics and Biosimilars	Adalimumab	Hadlima®	Yes - EDS	Yes - EDS
Manitoba	Biologics and Biosimilars	Adalimumab	Hyrimoz®	Yes - EDS	Yes - EDS
Manitoba	Biologics and Biosimilars	Adalimumab	Idacio®	Yes - EDS	Yes - EDS
Manitoba	Biologics and Biosimilars	Adalimumab	Amgevita®	Yes - EDS	Yes - EDS
Manitoba	Biologics and Biosimilars	Adalimumab	Hulio®	Yes - EDS	Yes - EDS
Manitoba	Biologics and Biosimilars	Adalimumab	Abrilada	Yes - EDS	Yes - EDS
Manitoba	Biologics and Biosimilars	Adalimumab	Simlandi	Yes - EDS	Yes - EDS
Manitoba	Biologics and Biosimilars	Adalimumab	Yuflyma	Yes - EDS	Yes - EDS
New Brunswick	Biologics and Biosimilars	Adalimumab	Humira®	No	No
New Brunswick	Biologics and Biosimilars	Adalimumab	Hadlima®	Yes - S/A	Yes - S/A
New Brunswick	Biologics and Biosimilars	Adalimumab	Hyrimoz®	Yes - S/A	Yes - S/A
New Brunswick	Biologics and Biosimilars	Adalimumab	Idacio®	Yes - S/A	Yes - S/A
New Brunswick	Biologics and Biosimilars	Adalimumab	Amgevita®	Yes - S/A	Yes - S/A
New Brunswick	Biologics and Biosimilars	Adalimumab	Hulio®	Yes - S/A	Yes - S/A
New Brunswick	Biologics and Biosimilars	Adalimumab	Abrilada	Yes – S/A	Yes – S/A
New Brunswick	Biologics and Biosimilars	Adalimumab	Simlandi	Yes – S/A	Yes – S/A
New Brunswick	Biologics and Biosimilars	Adalimumab	Yuflyma	Yes – S/A	Yes – S/A
Newfoundland and Labrador	Biologics and Biosimilars	Adalimumab	Humira®	Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira.	Yes - S/A All SA requests for coverage of adalimumab for adalimumab- naïve patients will be assessed for the biosimilars of adalimumab only. Patients whose initial Special Authority was received before April 17, 2021 will be eligible for coverage of Humira.
Newfoundland and Labrador	Biologics and Biosimilars	Adalimumab	Hadlima®	Yes - S/A	Yes - S/A
Newfoundland and Labrador	Biologics and Biosimilars	Adalimumab	Hyrimoz®	Yes - S/A	Yes - S/A
Newfoundland and Labrador	Biologics and Biosimilars	Adalimumab	Idacio®	Yes - S/A	Yes - S/A
Newfoundland and Labrador	Biologics and Biosimilars	Adalimumab	Amgevita®	Yes - S/A	Yes - S/A
Newfoundland and Labrador	Biologics and Biosimilars	Adalimumab	Hulio®	Yes - S/A	Yes - S/A
Newfoundland and Labrador	Biologics and Biosimilars	Adalimumab	Abrilada	Yes – S/A	Yes – S/A
Newfoundland and Labrador	Biologics and Biosimilars	Adalimumab	Simlandi	Yes – S/A	Yes – S/A
Newfoundland and Labrador	Biologics and Biosimilars	Adalimumab	Yuflyma	Yes – S/A	Yes – S/A
NIHB	Biologics and Biosimilars	Adalimumab	Humira®	Yes- only for clients who received approval for Humira before June 11, 2021	Yes- only for clients who received approval for Humira before June 11, 2021
NIHB	Biologics and Biosimilars	Adalimumab	Hadlima®	Yes - L/U	Yes - L/U
NIHB	Biologics and Biosimilars	Adalimumab	Hyrimoz®	Yes - L/U	Yes - L/U
NIHB	Biologics and Biosimilars	Adalimumab	Idacio®	Yes - L/U	Yes - L/U
NIHB	Biologics and Biosimilars	Adalimumab	Amgevita®	Yes - L/U	Yes - L/U
NIHB	Biologics and Biosimilars	Adalimumab	Hulio®	Yes - L/U	Yes - L/U
NIHB	Biologics and Biosimilars	Adalimumab	Abrilada	Yes – L/U	Yes – S/A
NIHB	Biologics and Biosimilars	Adalimumab	Simlandi	Yes - L/U	Yes - L/U
NIHB	Biologics and Biosimilars	Adalimumab	Yuflyma	Yes - L/U	Yes - L/U
Northwest Territories	Biologics and Biosimilars	Adalimumab	Humira®	Yes - L/U	Yes - L/U
Northwest Territories	Biologics and Biosimilars	Adalimumab	Hadlima®	Yes - L/U	Yes - L/U
Northwest Territories	Biologics and Biosimilars	Adalimumab	Hyrimoz®	Yes - L/U	Yes - L/U
Northwest Territories	Biologics and Biosimilars	Adalimumab	Idacio®	Yes - L/U	Yes - L/U
Northwest Territories	Biologics and Biosimilars	Adalimumab	Amgevita®	Yes - L/U	Yes - L/U
Northwest Territories	Biologics and Biosimilars	Adalimumab	Hulio®	Yes - L/U	Yes - L/U
Northwest Territories	Biologics and Biosimilars	Adalimumab	Abrilada	Yes - L/U	Yes - L/U
Northwest Territories	Biologics and Biosimilars	Adalimumab	Simlandi	Yes - L/U	Yes - L/U
Northwest Territories	Biologics and Biosimilars	Adalimumab	Yuflyma	Yes - L/U	Yes - L/U
Nova Scotia	Biologics and Biosimilars	Adalimumab	Humira®	Yes- only for clients who received approval for Humira before December 15, 2021	Yes- only for clients who received approval for Humira before December 15, 2021
Nova Scotia	Biologics and Biosimilars	Adalimumab	Hadlima®	Yes – EDS	Yes – EDS
Nova Scotia	Biologics and Biosimilars	Adalimumab	Hyrimoz®	Yes – EDS	Yes – EDS
Nova Scotia	Biologics and Biosimilars	Adalimumab	Idacio®	Yes – EDS	Yes – EDS
Nova Scotia	Biologics and Biosimilars	Adalimumab	Amgevita®	Yes – EDS	Yes – EDS
Nova Scotia	Biologics and Biosimilars	Adalimumab	Hulio®	Yes – EDS	Yes – EDS
Nova Scotia	Biologics and Biosimilars	Adalimumab	Abrilada	Yes – EDS	Yes – EDS
Nova Scotia	Biologics and Biosimilars	Adalimumab	Simlandi	Yes – EDS	Yes – EDS
Nova Scotia	Biologics and Biosimilars	Adalimumab	Yuflyma	Yes – EDS	Yes – EDS
Nunavut	Biologics and Biosimilars	Adalimumab	Abrilada	Yes - L/U	Yes - L/U
Nunavut	Biologics and Biosimilars	Adalimumab	Amgevita®	Yes - L/U	Yes - L/U
Nunavut	Biologics and Biosimilars	Adalimumab	Hadlima®	Yes - L/U	Yes - L/U
Nunavut	Biologics and Biosimilars	Adalimumab	Hulio®	Yes - L/U	Yes - L/U
Nunavut	Biologics and Biosimilars	Adalimumab	Humira®	Yes - L/U	Yes - L/U
Nunavut	Biologics and Biosimilars	Adalimumab	Hyrimoz®	Yes - L/U	Yes - L/U
Nunavut	Biologics and Biosimilars	Adalimumab	Idacio®	Yes - L/U	Yes - L/U
Ontario	Biologics and Biosimilars	Adalimumab	Abrilada	Yes - L/U	Yes - L/U
Ontario	Biologics and Biosimilars	Adalimumab	Amgevita®	Yes - L/U	Yes - L/U
Ontario	Biologics and Biosimilars	Adalimumab	Hadlima®	Yes - L/U	Yes - L/U
Ontario	Biologics and Biosimilars	Adalimumab	Hulio®	Yes - L/U	Yes - L/U
Ontario	Biologics and Biosimilars	Adalimumab	Humira®	Yes - EAP	Yes - EAP
Ontario	Biologics and Biosimilars	Adalimumab	Hyrimoz®	Yes - L/U	Yes - L/U
Ontario	Biologics and Biosimilars	Adalimumab	Idacio®	Yes - L/U	Yes - L/U
Ontario	Biologics and Biosimilars	Adalimumab	Simlandi	Yes - L/U	Yes - L/U
Ontario	Biologics and Biosimilars	Adalimumab	Yuflyma	Yes - L/U	Yes - L/U
Prince Edward Island	Biologics and Biosimilars	Adalimumab	Humira®	Yes - S/A	Yes - S/A
Prince Edward Island	Biologics and Biosimilars	Adalimumab	Hadlima®	Yes – S/A	Yes – S/A
Prince Edward Island	Biologics and Biosimilars	Adalimumab	Hyrimoz®	Yes – S/A	Yes – S/A
Prince Edward Island	Biologics and Biosimilars	Adalimumab	Idacio®	Yes – S/A	Yes – S/A
Prince Edward Island	Biologics and Biosimilars	Adalimumab	Amgevita®	Yes - S/A	Yes - S/A
Prince Edward Island	Biologics and Biosimilars	Adalimumab	Hulio®	Yes – S/A	Yes – S/A
Prince Edward Island	Biologics and Biosimilars	Adalimumab	Abrilada	Yes – S/A	Yes – S/A
Prince Edward Island	Biologics and Biosimilars	Adalimumab	Simlandi	Yes – S/A	Yes – S/A
Prince Edward Island	Biologics and Biosimilars	Adalimumab	Yuflyma	Yes – S/A	Yes – S/A
Quebec	Biologics and Biosimilars	Adalimumab	Humira®	Yes - S/A. If treatment began before August 19, 2020.	Yes - S/A. If treatment began before August 19, 2020.
Quebec	Biologics and Biosimilars	Adalimumab	Hadlima®	Yes - S/A	Yes - S/A
Quebec	Biologics and Biosimilars	Adalimumab	Hyrimoz®	Yes – S/A	Yes – S/A
Quebec	Biologics and Biosimilars	Adalimumab	Idacio®	Yes – S/A	Yes – S/A
Quebec	Biologics and Biosimilars	Adalimumab	Amgevita®	Yes – S/A	Yes – S/A
Quebec	Biologics and Biosimilars	Adalimumab	Hulio®	Yes – S/A	Yes – S/A
Quebec	Biologics and Biosimilars	Adalimumab	Abrilada	Yes – S/A	Yes – S/A
Quebec	Biologics and Biosimilars	Adalimumab	Simlandi	Yes – S/A	Yes – S/A
Quebec	Biologics and Biosimilars	Adalimumab	Yuflyma	Yes – S/A	Yes – S/A
Saskatchewan	Biologics and Biosimilars	Adalimumab	Humira®	No	No
Saskatchewan	Biologics and Biosimilars	Adalimumab	Hadlima®	Yes – EDS	Yes – EDS
Saskatchewan	Biologics and Biosimilars	Adalimumab	Hyrimoz®	Yes – EDS	Yes – EDS
Saskatchewan	Biologics and Biosimilars	Adalimumab	Idacio®	Yes – EDS	Yes – EDS
Saskatchewan	Biologics and Biosimilars	Adalimumab	Amgevita®	Yes – EDS	Yes – EDS
Saskatchewan	Biologics and Biosimilars	Adalimumab	Hulio®	Yes – EDS	Yes – EDS
Saskatchewan	Biologics and Biosimilars	Adalimumab	Abrilada	Yes – EDS	Yes – EDS
Saskatchewan	Biologics and Biosimilars	Adalimumab	Simlandi	Yes – EDS	Yes – EDS
Saskatchewan	Biologics and Biosimilars	Adalimumab	Yuflyma	Yes – EDS	Yes – EDS
Yukon	Biologics and Biosimilars	Adalimumab	Humira®	Yes - EDS	Yes - EDS
Yukon	Biologics and Biosimilars	Adalimumab	Hadlima®	Yes - EDS	Yes - EDS
Yukon	Biologics and Biosimilars	Adalimumab	Hyrimoz®	Yes - EDS	Yes - EDS
Yukon	Biologics and Biosimilars	Adalimumab	Idacio®	Yes - EDS	Yes - EDS
Yukon	Biologics and Biosimilars	Adalimumab	Amgevita®	Yes - EDS	Yes - EDS
Yukon	Biologics and Biosimilars	Adalimumab	Hulio®	Yes - EDS	Yes - EDS
Yukon	Biologics and Biosimilars	Adalimumab	Abrilada	Yes - EDS	Yes - EDS
Yukon	Biologics and Biosimilars	Adalimumab	Simlandi	Yes - EDS	Yes - EDS
Yukon	Biologics and Biosimilars	Adalimumab	Yuflyma	Yes - EDS	Yes - EDS
Nunavut	Biologics and Biosimilars	Adalimumab	Simlandi	Yes - L/U	Yes - L/U
Nunavut	Biologics and Biosimilars	Adalimumab	Yuflyma	Yes - L/U	Yes - L/U

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

Abrilada: https://pdf.hres.ca/dpd_pm/00068228.PDF
Amgevita®: https://pdf.hres.ca/dpd_pm/00067468.PDF
Hadlima®: https://pdf.hres.ca/dpd_pm/00068763.PDF
Hulio®: https://pdf.hres.ca/dpd_pm/00071858.PDF
Humira®: https://pdf.hres.ca/dpd_pm/00067414.PDF
Hyrimoz®: https://pdf.hres.ca/dpd_pm/00073497.PDF
Idacio®: https://pdf.hres.ca/dpd_pm/00058541.PDF
Simlandi: https://pdf.hres.ca/dpd_pm/00075380.PDF
Yuflyma: https://pdf.hres.ca/dpd_pm/00069429.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

AbbVie Care Support Program
https://abbviecare.ca/

Hadlima
Phone 1-866-556-5663 | https://harmonyorganon.ca/hadlima/en/index.html

Hyrimoz
Phone 1-888-6-SANDOZ (726369) | Email support.continum@sandoz.com

Idacio
Idacio KabiCare patient support program
https://kabicare.ca | Phone 1-888-304-2034| Email info@kabicare.ca

Amgevita
Enliven Services:
Phone: 1-877-936-2735 | Email amgevita@oneenliven.ca
www.amgevita.ca

Hulio
hulio.ca
Phone: 1-844-485-4677 | Email hulio@assistprogram.com

↑ Back to list of biologics and biosimilars

Infliximab (TNF Blocker)

How Does It Work?

Infliximab is a biologic that targets the overactive immune system in psoriasis. Infliximab works by supressing tumor necrosis factor-alpha (TNFa). Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Infliximab is an injectable medication that is administered intravenously, useful for psoriasis and psoriatic arthritis. Typically this is done in an infusion centre.

For plaque psoriasis:
5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter

For psoriatic arthritis:
5 mg/kg at 0, 2, and 6 weeks, followed by 5 mg/kg every 8 weeks thereafter.

What Are The Possible Side Effects?

The most common side effects of infliximab include temporary pain and redness around the infusion site, headaches, nausea, joint pain, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of infliximab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on infliximab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on infliximab.

Infliximab and other TNF inhibitory medications should be avoided in patients with or who have a close relative with multiple sclerosis. Infliximab should also be avoided in patients with severe heart failure. Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with infliximab include cyclosporine, echinacea, phenytoin, and warfarin. For a complete list of medications that may interact with infliximab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Province	Class	Generic Name	Drug Name	Psoriasis	Psoriatic Arthritis
Alberta	Biologics and Biosimilars	Infliximab	Remicade®	No	No
Alberta	Biologics and Biosimilars	Infliximab	Avsola®	Yes – S/A	Yes – S/A
Alberta	Biologics and Biosimilars	Infliximab	Inflectra®	Yes – S/A	Yes – S/A
British Columbia	Biologics and Biosimilars	Infliximab	Remicade®	No	No
British Columbia	Biologics and Biosimilars	Infliximab	Avsola®	Yes – S/A	Yes – S/A
British Columbia	Biologics and Biosimilars	Infliximab	Inflectra®	Yes – S/A	Yes – S/A
Manitoba	Biologics and Biosimilars	Infliximab	Remicade®	Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product.	Yes – EDS. Inflectra, Renflexis or Avsola will be the preferred infliximab option for all infliximab-naïve patients prescribed an infliximab product.
Manitoba	Biologics and Biosimilars	Infliximab	Avsola®	Yes - EDS	Yes - EDS
Manitoba	Biologics and Biosimilars	Infliximab	Inflectra®	Yes – EDS	Yes – EDS
New Brunswick	Biologics and Biosimilars	Infliximab	Remicade®	No	No
New Brunswick	Biologics and Biosimilars	Infliximab	Avsola®	Yes - S/A	Yes - S/A
New Brunswick	Biologics and Biosimilars	Infliximab	Inflectra®	Yes - S/A	Yes - S/A
Newfoundland and Labrador	Biologics and Biosimilars	Infliximab	Remicade®	Yes – S/A; Inflectra or Renflexis are the preferred infliximab therapy for treatment naïve patients (coverage will only be considered for Remicade in patients stabilized prior to June 1, 2016).	No
Newfoundland and Labrador	Biologics and Biosimilars	Infliximab	Avsola®	Yes - S/A	Yes - SA
Newfoundland and Labrador	Biologics and Biosimilars	Infliximab	Inflectra®	Yes – S/A	Yes – S/A
NIHB	Biologics and Biosimilars	Infliximab	Remicade®	No	No
NIHB	Biologics and Biosimilars	Infliximab	Avsola®	Yes - L/U	Yes - L/U
NIHB	Biologics and Biosimilars	Infliximab	Inflectra®	Yes - L/U	Yes - L/U
Northwest Territories	Biologics and Biosimilars	Infliximab	Remicade®	No	No
Northwest Territories	Biologics and Biosimilars	Infliximab	Avsola®	Yes - L/U	Yes - L/U
Northwest Territories	Biologics and Biosimilars	Infliximab	Inflectra®	Yes – L/U	Yes – L/U
Nova Scotia	Biologics and Biosimilars	Infliximab	Remicade®	Yes – S/A. For infliximab naïve patients whose infliximab therapy is initiated after June 1, 2016, an infliximab biosimilar will be the product approved.	Yes – S/A. For infliximab naïve patients whose infliximab therapy is initiated after June 1, 2016, an infliximab biosimilar will be the product approved.
Nova Scotia	Biologics and Biosimilars	Infliximab	Avsola®	Yes – EDS	Yes – EDS
Nova Scotia	Biologics and Biosimilars	Infliximab	Inflectra®	Yes – EDS	Yes – EDS
Nunavut	Biologics and Biosimilars	Infliximab	Avsola®	Yes - L/U	Yes - L/U
Nunavut	Biologics and Biosimilars	Infliximab	Inflectra®	Yes – L/U	Yes – L/U
Nunavut	Biologics and Biosimilars	Infliximab	Omvyence™	No	No
Nunavut	Biologics and Biosimilars	Infliximab	Remicade®	No	No
Nunavut	Biologics and Biosimilars	Infliximab	Remsima™	No	No
Nunavut	Biologics and Biosimilars	Infliximab	Renflexis®	Yes - L/U	Yes - L/U
Ontario	Biologics and Biosimilars	Infliximab	Avsola®	Yes – L/U	Yes – L/U
Ontario	Biologics and Biosimilars	Infliximab	Inflectra®	Yes – L/U	Yes – L/U
Ontario	Biologics and Biosimilars	Infliximab	Omvyence™	No	No
Prince Edward Island	Biologics and Biosimilars	Infliximab	Remicade®	Yes – S/A	Yes – S/A
Prince Edward Island	Biologics and Biosimilars	Infliximab	Avsola®	Yes – S/A	Yes – S/A
Prince Edward Island	Biologics and Biosimilars	Infliximab	Inflectra®	Yes – S/A	Yes – S/A
Quebec	Biologics and Biosimilars	Infliximab	Remicade®	Yes – S/A. If treatment began before August 19, 2020	Yes – S/A. If treatment began before August 19, 2020
Quebec	Biologics and Biosimilars	Infliximab	Avsola®	Yes - S/A	Yes - S/A
Quebec	Biologics and Biosimilars	Infliximab	Inflectra®	Yes - S/A	Yes - S/A
Saskatchewan	Biologics and Biosimilars	Infliximab	Remicade®	No	No
Saskatchewan	Biologics and Biosimilars	Infliximab	Avsola®	Yes – EDS	Yes – EDS
Saskatchewan	Biologics and Biosimilars	Infliximab	Inflectra®	Yes – EDS	Yes – EDS
Yukon	Biologics and Biosimilars	Infliximab	Remicade®	Yes – EDS; all new infliximab patients will be covered for Inflectra brand only.	Yes – EDS; all new infliximab patients will be covered for Inflectra brand only.
Yukon	Biologics and Biosimilars	Infliximab	Avsola®	No	No
Yukon	Biologics and Biosimilars	Infliximab	Inflectra®	Yes - EDS	Yes - EDS
Alberta	Biologics and Biosimilars	Infliximab	Omvyence™	No	No
Alberta	Biologics and Biosimilars	Infliximab	Remsima™	No	No
Alberta	Biologics and Biosimilars	Infliximab	Renflexis®	Yes – S/A	Yes – S/A
British Columbia	Biologics and Biosimilars	Infliximab	Omvyence™	No	No
British Columbia	Biologics and Biosimilars	Infliximab	Remsima™	No	No
British Columbia	Biologics and Biosimilars	Infliximab	Renflexis®	Yes – S/A	Yes – S/A
Manitoba	Biologics and Biosimilars	Infliximab	Omvyence™	No	No
Manitoba	Biologics and Biosimilars	Infliximab	Remsima™	No	No
Manitoba	Biologics and Biosimilars	Infliximab	Renflexis®	Yes – EDS	Yes – EDS
New Brunswick	Biologics and Biosimilars	Infliximab	Omvyence™	No	No
New Brunswick	Biologics and Biosimilars	Infliximab	Remsima™	No	No
New Brunswick	Biologics and Biosimilars	Infliximab	Renflexis®	Yes - S/A	Yes - S/A
Newfoundland and Labrador	Biologics and Biosimilars	Infliximab	Omvyence™	No	No
Newfoundland and Labrador	Biologics and Biosimilars	Infliximab	Remsima™	No	No
Newfoundland and Labrador	Biologics and Biosimilars	Infliximab	Renflexis®	Yes – S/A	Yes – S/A
NIHB	Biologics and Biosimilars	Infliximab	Omvyence™	No	No
NIHB	Biologics and Biosimilars	Infliximab	Remsima™	No	No
NIHB	Biologics and Biosimilars	Infliximab	Renflexis®	Yes - L/U	Yes - L/U
Northwest Territories	Biologics and Biosimilars	Infliximab	Omvyence™	No	No
Northwest Territories	Biologics and Biosimilars	Infliximab	Remsima™	No	No
Northwest Territories	Biologics and Biosimilars	Infliximab	Renflexis®	Yes - L/U	Yes - L/U
Nova Scotia	Biologics and Biosimilars	Infliximab	Omvyence™	No	No
Nova Scotia	Biologics and Biosimilars	Infliximab	Remsima™	No	No
Nova Scotia	Biologics and Biosimilars	Infliximab	Renflexis®	Yes – EDS	Yes – EDS
Ontario	Biologics and Biosimilars	Infliximab	Remicade®	Yes - EAP	Yes - EAP
Ontario	Biologics and Biosimilars	Infliximab	Remsima™	No	No
Ontario	Biologics and Biosimilars	Infliximab	Renflexis®	Yes – L/U	Yes – L/U
Prince Edward Island	Biologics and Biosimilars	Infliximab	Omvyence™	No	No
Prince Edward Island	Biologics and Biosimilars	Infliximab	Remsima™	No	No
Prince Edward Island	Biologics and Biosimilars	Infliximab	Renflexis®	Yes – S/A	Yes – S/A
Quebec	Biologics and Biosimilars	Infliximab	Omvyence™	No	No
Quebec	Biologics and Biosimilars	Infliximab	Remsima™	No	No
Quebec	Biologics and Biosimilars	Infliximab	Renflexis®	Yes - S/A	Yes - S/A
Saskatchewan	Biologics and Biosimilars	Infliximab	Omvyence™	No	No
Saskatchewan	Biologics and Biosimilars	Infliximab	Remsima™	No	No
Saskatchewan	Biologics and Biosimilars	Infliximab	Renflexis®	Yes – EDS	Yes – EDS
Yukon	Biologics and Biosimilars	Infliximab	Omvyence™	No	No
Yukon	Biologics and Biosimilars	Infliximab	Remsima™	No	No
Yukon	Biologics and Biosimilars	Infliximab	Renflexis®	Yes - EDS	Yes - EDS

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

Avsola®: https://pdf.hres.ca/dpd_pm/00065940.PDF
Inflectra®: https://pdf.hres.ca/dpd_pm/00057004.PDF
Omvyence™: https://pdf.hres.ca/dpd_pm/00068865.PDF
Remicade®: https://pdf.hres.ca/dpd_pm/00075118.PDF
Remsima™: https://pdf.hres.ca/dpd_pm/00074581.PDF
Renflexis®: https://pdf.hres.ca/dpd_pm/00072737.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Infliximab (Remicade^®): https://www.bioadvancemember.ca/en/global/home
Infliximab biosimilar Inflectra^®: https://www.pfizer.ca/assistance-programs
Infliximab biosimilar Renflexis^®: http://www.merckharmony.ca/

Avsola
Enliven Services
Ph: 1-877-9ENBREL (936-2735) | Email info@oneenliven.ca
www.enbrel.ca; www.avsola.ca

Remsima
CELLTRION CONNECT™ patient support program for Remsima
Interested individuals can find out more about CELLTRION CONNECT™ by visiting www.celltrionconnect.ca/

↑ Back to list of biologics and biosimilars

Certolizumab pegol (TNF Blocker)

How Does It Work?

Certolizumab is a biologic that targets the overactive immune system in psoriasis. Certolizumab works by supressing tumor necrosis factor-alpha (TNFa).

Useful in psoriasis and psoriatic arthritis.

How Is It Used?

Certolizumab is an injectable medication that is administered subcutaneously.

For plaque psoriasis:
400 mg every 2 weeks

For psoriatic arthritis:
400 mg at weeks 0, 2, and 4, followed by 200 mg every 2 weeks

What Are The Possible Side Effects?

The most common side effects of certolizumab include joint pain, and an increased risk of upper respiratory tract infections and urinary tract infections. To obtain a comprehensive list of all known potential side effects of certolizumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on certolizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on certolizumab.

Certolizumab should be avoided in patients with moderate to severe heart failure.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with certolizumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with certolizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Province	Class	Generic Name	Drug Name	Psoriasis	Psoriatic Arthritis
Alberta	Biologics and Biosimilars	Certolizumab pegol	Cimzia®	No	Yes – S/A
British Columbia	Biologics and Biosimilars	Certolizumab pegol	Cimzia®	No	Yes - S/A
Manitoba	Biologics and Biosimilars	Certolizumab pegol	Cimzia®	No	Yes – EDS
New Brunswick	Biologics and Biosimilars	Certolizumab pegol	Cimzia®	No	Yes – S/A
Newfoundland and Labrador	Biologics and Biosimilars	Certolizumab pegol	Cimzia®	No	Yes – S/A
NIHB	Biologics and Biosimilars	Certolizumab pegol	Cimzia®	No	Yes – L/U
Northwest Territories	Biologics and Biosimilars	Certolizumab pegol	Cimzia®	No	Yes – L/U
Nova Scotia	Biologics and Biosimilars	Certolizumab pegol	Cimzia®	No	Yes – EDS
Nunavut	Biologics and Biosimilars	Certolizumab pegol	Cimzia®	No	Yes – L/U
Ontario	Biologics and Biosimilars	Certolizumab pegol	Cimzia®	No	Yes – EAP
Prince Edward Island	Biologics and Biosimilars	Certolizumab pegol	Cimzia®	No	Yes – S/A
Quebec	Biologics and Biosimilars	Certolizumab pegol	Cimzia®	No	Yes – S/A
Saskatchewan	Biologics and Biosimilars	Certolizumab pegol	Cimzia®	No	Yes – EDS
Yukon	Biologics and Biosimilars	Certolizumab pegol	Cimzia®	No	Yes – EDS

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00053920.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

UCB Cares 1-800-908-5555

↑ Back to list of biologics and biosimilars

Golimumab (TNF Blocker)

How Does It Work?

Golimumab is a biologic that targets the overactive immune system in psoriatic arthritis. Golimumab works by supressing tumor necrosis factor-alpha (TNFa).

How Is It Used?

Golimumab is a biologic medication that can be administered either subcutaneously or intravenously.

What Are The Possible Side Effects?

The most common side effects of golimumab are an increased risk of infection and a temporary injection site reaction. To obtain a comprehensive list of all known potential side effects of golimumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on golimumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on golimumab.

Golimumab should be avoided in patients with severe heart failure.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with golimumab include abatacept, anakinra, baricitinib, belimumab, canakizumab, certolizumab pegol, cladribine, echinacea, infliximab, leflunomide, natalizumab, pimecrolimus, rilonacept, roflumilast, tacrolimus, tocilizumab, tofacitinib, and vedolizumab. For a complete list of medications that may interact with golimumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Province	Class	Generic Name	Drug Name	Psoriasis	Psoriatic Arthritis
Alberta	Biologics and Biosimilars	Golimumab	Simponi®	N/A	Yes – S/A
British Columbia	Biologics and Biosimilars	Golimumab	Simponi®	N/A	Yes – S/A
Manitoba	Biologics and Biosimilars	Golimumab	Simponi®	N/A	Yes – EDS
New Brunswick	Biologics and Biosimilars	Golimumab	Simponi®	N/A	Yes – S/A
Newfoundland and Labrador	Biologics and Biosimilars	Golimumab	Simponi®	N/A	Yes – S/A
NIHB	Biologics and Biosimilars	Golimumab	Simponi®	N/A	Yes – L/U
Northwest Territories	Biologics and Biosimilars	Golimumab	Simponi®	N/A	Yes – L/U
Nova Scotia	Biologics and Biosimilars	Golimumab	Simponi®	No	Yes – EDS
Ontario	Biologics and Biosimilars	Golimumab	Simponi®	N/A	Yes - EAP
Prince Edward Island	Biologics and Biosimilars	Golimumab	Simponi®	No	Yes – S/A
Quebec	Biologics and Biosimilars	Golimumab	Simponi®	N/A	Yes – S/A
Saskatchewan	Biologics and Biosimilars	Golimumab	Simponi®	No	Yes – EDS
Yukon	Biologics and Biosimilars	Golimumab	Simponi®	N/A	Yes – EDS
Nunavut	Biologics and Biosimilars	Golimumab	Simponi®	N/A	Yes – L/U

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00074084.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

https://www.bioadvancemember.ca/en/global/home

↑ Back to list of biologics and biosimilars

Ixekizumab (IL17 Blocker)

How Does It Work?

Ixekizumab is a biologic that targets the overactive immune system in psoriasis. Ixekizumab works by supressing interleukin-17A. Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Ixekizumab is an injectable medication that is administered subcutaneously.

For plaque psoriasis:
160 mg once, followed by 80 mg at weeks 2, 4, 6, 8, 10 and 12, and then 80 mg every 4 weeks

For psoriatic arthritis:
160 mg once, followed by 80 mg every 4 weeks

What Are The Possible Side Effects?

The most common side effects of ixekizumab include temporary pain and redness around the injection site, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of ixekizumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on ixekizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on ixekizumab.

Ixekizumab should be avoided in patients with currently active or previous history of inflammatory bowel disease.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with ixekizumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with ixekizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Province	Class	Generic Name	Drug Name	Psoriasis	Psoriatic Arthritis
Alberta	Biologics and Biosimilars	Ixekizumab	Taltz®	Yes – S/A	Yes – S/A
British Columbia	Biologics and Biosimilars	Ixekizumab	Taltz®	Yes – S/A	Yes – S/A
Manitoba	Biologics and Biosimilars	Ixekizumab	Taltz®	Yes – EDS	Yes – EDS
Manitoba	Biologics and Biosimilars	Ixekizumab	Siliq™	Yes – EDS	N/A
New Brunswick	Biologics and Biosimilars	Ixekizumab	Taltz®	Yes – S/A	Yes – S/A
Newfoundland and Labrador	Biologics and Biosimilars	Ixekizumab	Taltz®	Yes – S/A	Yes – S/A
NIHB	Biologics and Biosimilars	Ixekizumab	Taltz®	Yes – L/U	Yes – L/U
Northwest Territories	Biologics and Biosimilars	Ixekizumab	Taltz®	Yes – L/U	Yes – L/U
Nova Scotia	Biologics and Biosimilars	Ixekizumab	Taltz®	Yes – EDS	Yes – EDS
Ontario	Biologics and Biosimilars	Ixekizumab	Taltz®	Yes – L/U	Yes - EAP
Prince Edward Island	Biologics and Biosimilars	Ixekizumab	Taltz®	Yes – S/A	Yes – S/A
Quebec	Biologics and Biosimilars	Ixekizumab	Taltz®	Yes – S/A	Yes – S/A
Saskatchewan	Biologics and Biosimilars	Ixekizumab	Taltz®	Yes – EDS	Yes – EDS
Yukon	Biologics and Biosimilars	Ixekizumab	Taltz®	Yes - EDS	Yes - EDS
Nunavut	Biologics and Biosimilars	Ixekizumab	Taltz®	Yes – L/U	Yes – L/U

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00069828.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Call 1-877-219-8908 for information.

↑ Back to list of biologics and biosimilars

Brodalumab (IL17 Blocker)

How Does It Work?

Brodalumab is a biologic that targets the overactive immune system in psoriasis. Brodalumab works by preventing interleukin-17 from causing inflammation.

How Is It Used?

Brodalumab is an injectable medication that is administered subcutaneously.

For plaque psoriasis:
210 mg at weeks 0, 1, and 2, followed by 210 mg once every 2 weeks

What Are The Possible Side Effects?

The most common side effect of brodalumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of brodalumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on brodalumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on brodalumab.

Brodalumab should be avoided in patients with Crohn’s disease.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with brodalumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with brodalumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Province	Class	Generic Name	Drug Name	Psoriasis	Psoriatic Arthritis
Alberta	Biologics and Biosimilars	Brodalumab	Siliq™	No	N/A
British Columbia	Biologics and Biosimilars	Brodalumab	Siliq™	No	N/A
New Brunswick	Biologics and Biosimilars	Brodalumab	Siliq™	Yes – S/A	N/A
Newfoundland and Labrador	Biologics and Biosimilars	Brodalumab	Siliq™	Yes – S/A	N/A
NIHB	Biologics and Biosimilars	Brodalumab	Siliq™	Yes – L/U	N/A
Northwest Territories	Biologics and Biosimilars	Brodalumab	Siliq™	Yes – L/U	N/A
Nova Scotia	Biologics and Biosimilars	Brodalumab	Siliq™	Yes – EDS	N/A
Ontario	Biologics and Biosimilars	Brodalumab	Siliq™	Yes – L/U	N/A
Prince Edward Island	Biologics and Biosimilars	Brodalumab	Siliq™	Yes – S/A	N/A
Quebec	Biologics and Biosimilars	Brodalumab	Siliq™	Yes – S/A	N/A
Saskatchewan	Biologics and Biosimilars	Brodalumab	Siliq™	Yes – EDS	No
Yukon	Biologics and Biosimilars	Brodalumab	Siliq™	No	N/A
Nunavut	Biologics and Biosimilars	Brodalumab	Siliq™	Yes – L/U	N/A

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00075300.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Call 1-844-852-6967 for information.

↑ Back to list of biologics and biosimilars

Secukinumab (IL17 Blocker)

How Does It Work?

Secukinumab is a biologic that targets the overactive immune system in psoriasis. Secukinumab works by supressing interleukin-17A. Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Secukinumab is an injectable medication that is administered subcutaneously.

For plaque psoriasis:
300 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks

For psoriatic arthritis:
For patients not treated previously by a biological agent – 150 mg (or 300 mg for some patients) once weekly at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks. For those with previous treatment with a biologic agent – 300 mg once weekly at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks.

What Are The Possible Side Effects?

The most common side effect of secukinumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of secukinumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on secukinumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on secukinumab.

Secukinumab should be avoided in patients with currently active or previous history of inflammatory bowel disease.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with secukinumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with secukinumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Province	Class	Generic Name	Drug Name	Psoriasis	Psoriatic Arthritis
Nunavut	Biologics and Biosimilars	Secukinumab	Cosentyx®	Yes – L/U	Yes – L/U
Alberta	Biologics and Biosimilars	Secukinumab	Cosentyx®	Yes – S/A	Yes – S/A
British Columbia	Biologics and Biosimilars	Secukinumab	Cosentyx®	Yes – S/A	Yes – S/A
Manitoba	Biologics and Biosimilars	Secukinumab	Cosentyx®	Yes – EDS	Yes – EDS
New Brunswick	Biologics and Biosimilars	Secukinumab	Cosentyx®	Yes – S/A	Yes – S/A
Newfoundland and Labrador	Biologics and Biosimilars	Secukinumab	Cosentyx®	Yes – S/A	Yes – S/A
NIHB	Biologics and Biosimilars	Secukinumab	Cosentyx®	Yes – L/U	Yes – L/U
Northwest Territories	Biologics and Biosimilars	Secukinumab	Cosentyx®	Yes – L/U	Yes – L/U
Nova Scotia	Biologics and Biosimilars	Secukinumab	Cosentyx®	Yes – EDS	Yes - EDS
Ontario	Biologics and Biosimilars	Secukinumab	Cosentyx®	Yes – L/U	Yes - EAP
Prince Edward Island	Biologics and Biosimilars	Secukinumab	Cosentyx®	Yes – S/A	Yes – S/A
Quebec	Biologics and Biosimilars	Secukinumab	Cosentyx®	Yes – S/A	Yes – S/A
Saskatchewan	Biologics and Biosimilars	Secukinumab	Cosentyx®	Yes – EDS	Yes – EDS
Yukon	Biologics and Biosimilars	Secukinumab	Cosentyx®	Yes – EDS	Yes – EDS

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00075631.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

https://www.cosentyx.ca/home/plaque-psoriasis/xpose-your-support-network/

↑ Back to list of biologics and biosimilars

Bimekizumab (IL17 Blocker)

How Does It Work?

Bimekizumab works by inhibiting the inflammatory proteins known as IL-17A and IL-17F. These inflammatory proteins are present in increased levels in psoriasis and by inhibiting them, this medication can help to achieve skin clearance and improvement in psoriasis symptoms.

How Is It Used?

Bimekizumab is an injectable medication that is administered subcutaneously. Patients can self-inject at home.

Bimekizumab is approved for the treatment of psoriasis. The recommended dose is 320mg (given as 2 subcutaneous injections of 160mg each) every 4 weeks for the first 16 weeks and then every 8 weeks thereafter.
If you weigh more than 120 kg, your healthcare professional may decide to continue your injections every 4 weeks from week 16. Follow your doctor’s instructions for optimal dosing.

Bimekizumab is available as a pre-filled syringe or autoinjector.

What Are The Possible Side Effects?

The most common side effects of bimekizumab include an increased risk of upper respiratory tract infection. To obtain a comprehensive list of all known potential side effects of bimekizumab, talk to your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on bimekizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is safe to receive while on bimekizumab.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

Bimekizumab is not recommended in patients with inflammatory bowel disease.

What Medications Interact With This Treatment?

For a complete list of medications that may interact with bimekizumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Province	Class	Generic Name	Drug Name	Psoriasis	Psoriatic Arthritis
Alberta	Biologics and Biosimilars	Bimekizumab	Bimzelx	Yes – S/A	No
British Columbia	Biologics and Biosimilars	Bimekizumab	Bimzelx	Yes - S/A	No
Manitoba	Biologics and Biosimilars	Bimekizumab	Bimzelx	Yes - EDS	No
New Brunswick	Biologics and Biosimilars	Bimekizumab	Bimzelx	Yes – S/A	No
Newfoundland and Labrador	Biologics and Biosimilars	Bimekizumab	Bimzelx	Yes – S/A	No
NIHB	Biologics and Biosimilars	Bimekizumab	Bimzelx	No	No
Northwest Territories	Biologics and Biosimilars	Bimekizumab	Bimzelx	No	No
Nova Scotia	Biologics and Biosimilars	Bimekizumab	Bimzelx	Yes – EDS	No
Nunavut	Biologics and Biosimilars	Bimekizumab	Bimzelx	No	No
Ontario	Biologics and Biosimilars	Bimekizumab	Bimzelx	Yes - L/U	No
Prince Edward Island	Biologics and Biosimilars	Bimekizumab	Bimzelx	Yes – S/A	No
Quebec	Biologics and Biosimilars	Bimekizumab	Bimzelx	Yes – S/A	No
Saskatchewan	Biologics and Biosimilars	Bimekizumab	Bimzelx	Yes - EDS	No
Yukon	Biologics and Biosimilars	Bimekizumab	Bimzelx	No	No

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00074908.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

UCBCares Patient Support Program
1-800-908-5555
www.UCBCares.ca

↑ Back to list of biologics and biosimilars

Ustekinumab (IL12/23 Blocker)

How Does It Work?

Ustekinumab is a biologic that targets the overactive immune system in psoriasis. Ustekinumab works by suppressing interleukin 12 and interleukin 23. Useful for psoriasis and psoriatic arthritis.

How Is It Used?

Ustekinumab is an injectable medication that is administered subcutaneously. Can be home dosed.

For plaque psoriasis:
≤100 kg: 45 mg at 0 and 4 weeks, and then every 12 weeks thereafter
>100 kg: 90 mg at 0 and 4 weeks, and then every 12 weeks thereafter

For psoriatic arthritis:
45 mg at 0 and 4 weeks, and then every 12 weeks thereafter.

What Are The Possible Side Effects?

The most common side effect of ustekinumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of ustekinumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on ustekinumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on ustekinumab.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

Some medications that may interact with ustekinumab include denosumab, echinacea, and trastuzumab. For a complete list of medications that may interact with ustekinumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Province	Class	Generic Name	Drug Name	Psoriasis	Psoriatic Arthritis
Alberta	Biologics and Biosimilars	Ustekinumab	Stelara®	Yes – S/A	No
Alberta	Biologics and Biosimilars	Ustekinumab	Wezlana	Yes – S/A	No
Alberta	Biologics and Biosimilars	Ustekinumab	Jamteki	Yes – S/A	No
British Columbia	Biologics and Biosimilars	Ustekinumab	Stelara®	Yes – S/A until Dec 3 2024	No
British Columbia	Biologics and Biosimilars	Ustekinumab	Jamteki	Yes - S/A	Yes - S/A
Manitoba	Biologics and Biosimilars	Ustekinumab	Stelara®	Yes – EDS	No
New Brunswick	Biologics and Biosimilars	Ustekinumab	Stelara®	No	No
New Brunswick	Biologics and Biosimilars	Ustekinumab	Jamteki	Yes - S/A	Yes - S/A
New Brunswick	Biologics and Biosimilars	Ustekinumab	Wezlana	Yes - S/A	Yes - S/A
Newfoundland and Labrador	Biologics and Biosimilars	Ustekinumab	Stelara®	Yes – S/A	No
Newfoundland and Labrador	Biologics and Biosimilars	Ustekinumab	Jamteki	Yes – S/A	Yes – S/A
Newfoundland and Labrador	Biologics and Biosimilars	Ustekinumab	Wezlana	Yes – S/A	Yes – S/A
NIHB	Biologics and Biosimilars	Ustekinumab	Stelara®	Yes – L/U	No
NIHB	Biologics and Biosimilars	Ustekinumab	Wezlana	Yes - L/U	Yes - L/U
Northwest Territories	Biologics and Biosimilars	Ustekinumab	Stelara®	Yes – L/U	No
Northwest Territories	Biologics and Biosimilars	Ustekinumab	Wezlana	Yes – L/U	Yes – L/U
Nova Scotia	Biologics and Biosimilars	Ustekinumab	Stelara®	Yes - EDS	No
Nova Scotia	Biologics and Biosimilars	Ustekinumab	Jamteki	Yes - EDS	Yes - EDS
Nova Scotia	Biologics and Biosimilars	Ustekinumab	Wezlana	Yes - EDS	Yes - EDS
Nunavut	Biologics and Biosimilars	Ustekinumab	Stelara®	Yes – L/U	No
Nunavut	Biologics and Biosimilars	Ustekinumab	Wezlana	Yes – L/U	Yes – L/U
Ontario	Biologics and Biosimilars	Ustekinumab	Stelara®	Yes – L/U	No
Ontario	Biologics and Biosimilars	Ustekinumab	Jamteki	Yes - L/U	Yes - L/U
Ontario	Biologics and Biosimilars	Ustekinumab	Wezlana	Yes - L/U	Yes - L/U
Prince Edward Island	Biologics and Biosimilars	Ustekinumab	Stelara®	Yes – S/A	No
Quebec	Biologics and Biosimilars	Ustekinumab	Stelara®	Yes – S/A	Yes – S/A
Quebec	Biologics and Biosimilars	Ustekinumab	Jamteki	Yes – S/A	Yes – S/A
Quebec	Biologics and Biosimilars	Ustekinumab	Wezlana	Yes – S/A	Yes – S/A
Saskatchewan	Biologics and Biosimilars	Ustekinumab	Stelara®	Yes – EDS	Yes – EDS
Yukon	Biologics and Biosimilars	Ustekinumab	Stelara®	Yes – EDS	No

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

Jamteki: https://pdf.hres.ca/dpd_pm/00073286.PDF
Stelara®: https://pdf.hres.ca/dpd_pm/00073994.PDF
Wezlana: https://pdf.hres.ca/dpd_pm/00073953.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

https://www.bioadvancemember.ca/en/global/home

↑ Back to list of biologics and biosimilars

Risankizumab (IL23 Blocker)

How Does It Work?

Risankizumab is a biologic that targets the overactive immune system in psoriasis. Risankizumab works by supressing interleukin-23A.

How Is It Used?

The recommended dose of SKYRIZI is 150 mg (two 75 mg injections) administered by subcutaneous injection at Week 0, Week 4, and every 12 weeks thereafter.

What Are The Possible Side Effects?

The most common side effect of risankizumab is an increased risk of infection. To obtain a comprehensive list of all known potential side effects of risankizumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on risankizumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on risankizumab.

Patients should be screened for tuberculosis and some invasive fungal infections prior to treatment.

What Medications Interact With This Treatment?

N/A

Province	Class	Generic Name	Drug Name	Psoriasis	Psoriatic Arthritis
Alberta	Biologics and Biosimilars	Risankizumab	Skyrizi™	Yes – S/A	N/A
British Columbia	Biologics and Biosimilars	Risankizumab	Skyrizi™	Yes – S/A	N/A
Manitoba	Biologics and Biosimilars	Risankizumab	Skyrizi™	Yes – EDS	N/A
New Brunswick	Biologics and Biosimilars	Risankizumab	Skyrizi™	Yes – S/A	N/A
Newfoundland and Labrador	Biologics and Biosimilars	Risankizumab	Skyrizi™	Yes – S/A	N/A
NIHB	Biologics and Biosimilars	Risankizumab	Skyrizi™	Yes – L/U	N/A
Northwest Territories	Biologics and Biosimilars	Risankizumab	Skyrizi™	Yes – L/U	N/A
Nova Scotia	Biologics and Biosimilars	Risankizumab	Skyrizi™	Yes – EDS	N/A
Nunavut	Biologics and Biosimilars	Risankizumab	Skyrizi™	Yes – L/U	N/A
Ontario	Biologics and Biosimilars	Risankizumab	Skyrizi™	Yes – L/U	N/A
Prince Edward Island	Biologics and Biosimilars	Risankizumab	Skyrizi™	Yes – S/A	N/A
Quebec	Biologics and Biosimilars	Risankizumab	Skyrizi™	Yes – S/A	N/A
Saskatchewan	Biologics and Biosimilars	Risankizumab	Skyrizi™	Yes – EDS	N/A
Yukon	Biologics and Biosimilars	Risankizumab	Skyrizi™	Yes – EDS	N/A

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00075159.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

https://abbviecare.ca/

↑ Back to list of biologics and biosimilars

Guselkumab (IL23 Blocker)

How Does It Work?

Guselkumab is a biologic that targets the overactive immune system in psoriasis. Guselkumab works by neutralizing interleukin-23.

How Is It Used?

Guselkumab is an injectable medication that is administered subcutaneously by injection. Guselkumab can be used alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) such as methotrexate.

For plaque psoriasis:
100 mg at weeks 0 and 4, and then every 8 weeks thereafter

For psoriatic arthritis:
100 mg at weeks 0 and 4, and then every 8 weeks thereafter

The most common side effect of guselkumab is an increased risk of respiratory tract infections. To obtain a comprehensive list of all known potential side effects of guselkumab, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on guselkumab. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on guselkumab.

Patients should be screened for tuberculosis and infections prior to treatment.

Do not use TREMFYA^®/TREMFYA One-Press™ if you are allergic to guselkumab or any of the ingredients in TREMFYA^®/TREMFYA OnePress™.

If you think you are allergic, ask your healthcare professional for advice before using TREMFYA^®/TREMFYA One-Press™.

What Medications Interact With This Treatment?

For a complete list of medications that may interact with guselkumab and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Province	Class	Generic Name	Drug Name	Psoriasis	Psoriatic Arthritis
Alberta	Biologics and Biosimilars	Guselkumab	Tremfya®	Yes - S/A	Yes - S/A
British Columbia	Biologics and Biosimilars	Guselkumab	Tremfya®	No	No
Manitoba	Biologics and Biosimilars	Guselkumab	Tremfya®	Yes - EDS	Yes - EDS
New Brunswick	Biologics and Biosimilars	Guselkumab	Tremfya®	Yes – S/A	Yes – S/A
Newfoundland and Labrador	Biologics and Biosimilars	Guselkumab	Tremfya®	Yes – S/A	Yes – S/A
NIHB	Biologics and Biosimilars	Guselkumab	Tremfya®	Yes - L/U	Yes - L/U
Northwest Territories	Biologics and Biosimilars	Guselkumab	Tremfya®	Yes - L/U	Yes - L/U
Nova Scotia	Biologics and Biosimilars	Guselkumab	Tremfya®	Yes – EDS	Yes – EDS
Ontario	Biologics and Biosimilars	Guselkumab	Tremfya®	Yes - L/U	Yes - EAP
Prince Edward Island	Biologics and Biosimilars	Guselkumab	Tremfya®	Yes – S/A	Yes – S/A
Quebec	Biologics and Biosimilars	Guselkumab	Tremfya®	Yes - S/A	No
Saskatchewan	Biologics and Biosimilars	Guselkumab	Tremfya®	Yes - EDS	Yes - EDS
Yukon	Biologics and Biosimilars	Guselkumab	Tremfya®	No	No
Nunavut	Biologics and Biosimilars	Guselkumab	Tremfya®	Yes - L/U	Yes - L/U

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00075605.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

https://www.bioadvancemember.ca/en/global/home

↑ Back to list of biologics and biosimilars

Abatacept

How Does It Work?

Abatacept is a biologic that targets the overactive immune system in psoriatic arthritis. Abatacept works by supressing the activation of white blood cells called T-cells.

How Is It Used?

Abatacept is a biologic medication that can be administered either subcutaneously or intravenously.

What Are The Possible Side Effects?

The most common side effects of abatacept are headache, nausea, and an increased risk of infection. To obtain a comprehensive list of all known potential side effects of abatacept, talk your doctor or pharmacist.

Any Other Important Considerations?

Some vaccinations, known as live vaccinations, should be avoided while on abatacept. Before receiving a vaccination, ask your healthcare provider if the vaccine is ok to receive while on abatacept.

Patients with chronic obstructive pulmonary disease (COPD) are at an increased risk of experience COPD-related adverse events such as cough, shortness of breath, and infection while on abatacept.

Abatacept should be avoided in patients who are immunocompromised or HIV positive.

What Medications Interact With This Treatment?

Some medications that may interact with abatacept include anakinra, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab, baricitinib, belimumab, cladribine, echinacea, leflunomide, natalizumab, pimecrolimus, rituximab, roflumilast, tacrolimus, tocilizumab, and tofacitinib. For a complete list of medications that may interact with abatacept and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Province	Class	Generic Name	Drug Name	Psoriasis	Psoriatic Arthritis
Alberta	Biologics and Biosimilars	Abatacept	Orencia®	No	No
British Columbia	Biologics and Biosimilars	Abatacept	Orencia®	No	No
Manitoba	Biologics and Biosimilars	Abatacept	Orencia®	No	No
New Brunswick	Biologics and Biosimilars	Abatacept	Orencia®	No	No
Newfoundland and Labrador	Biologics and Biosimilars	Abatacept	Orencia®	No	No
NIHB	Biologics and Biosimilars	Abatacept	Orencia®	No	No
Northwest Territories	Biologics and Biosimilars	Abatacept	Orencia®	No	No
Nova Scotia	Biologics and Biosimilars	Abatacept	Orencia®	No	No
Nunavut	Biologics and Biosimilars	Abatacept	Orencia®	No	No
Ontario	Biologics and Biosimilars	Abatacept	Orencia®	N/A	No. EAP may cover in specific clinical circumstances.
Prince Edward Island	Biologics and Biosimilars	Abatacept	Orencia®	No	No
Quebec	Biologics and Biosimilars	Abatacept	Orencia®	No	No
Saskatchewan	Biologics and Biosimilars	Abatacept	Orencia®	No	No
Yukon	Biologics and Biosimilars	Abatacept	Orencia®	No	No

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00070861.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

↑ Back to list of biologics and biosimilars

Tildrakizumab

How Does It Work?

Ilumya™ acts on specific molecular signals used by the immune system to decrease the immune system’s overactivity that can contribute to plaque psoriasis.

How Is It Used?

Ilumya™ is a drug taken by injection often in 12-week intervals.

What Are The Possible Side Effects?

Side effects of Ilumya™ can include diarrhea, skin irritation and muscle pain at the injection site, fatigue, increased risk of infection, joint pain, and headaches. To obtain a comprehensive list of all potential side effects, talk to your doctor or pharmacist.

Any Other Important Considerations?

Not applicable

What Medications Interact With This Treatment?

Certain vaccines cannot be taken while on Ilumya™. Talk to your doctor before being vaccinated to confirm it is safe to do so while on Ilumya. Ilumya may also interact with dextromethorphan. Ask your doctor or pharmacist if you are concerned about a drug interaction.

Province	Class	Generic Name	Drug Name	Psoriasis	Psoriatic Arthritis
Nunavut	Biologics and Biosimilars	Tildrakizumab	Ilumya™	No	N/A
Alberta	Biologics and Biosimilars	Tildrakizumab	Ilumya™	Yes - SA	N/A
British Columbia	Biologics and Biosimilars	Tildrakizumab	Ilumya™	No	N/A
Manitoba	Biologics and Biosimilars	Tildrakizumab	Ilumya™	Yes - EDS	N/A
New Brunswick	Biologics and Biosimilars	Tildrakizumab	Ilumya™	Yes - SA	N/A
Newfoundland and Labrador	Biologics and Biosimilars	Tildrakizumab	Ilumya™	Yes – S/A	N/A
NIHB	Biologics and Biosimilars	Tildrakizumab	Ilumya™	Yes – L/U	N/A
Northwest Territories	Biologics and Biosimilars	Tildrakizumab	Ilumya™	No	N/A
Nova Scotia	Biologics and Biosimilars	Tildrakizumab	Ilumya™	Yes – EDS	N/A
Ontario	Biologics and Biosimilars	Tildrakizumab	Ilumya™	Yes - L/U	N/A
Prince Edward Island	Biologics and Biosimilars	Tildrakizumab	Ilumya™	Yes – S/A	N/A
Quebec	Biologics and Biosimilars	Tildrakizumab	Ilumya™	No	N/A
Saskatchewan	Biologics and Biosimilars	Tildrakizumab	Ilumya™	Yes - EDS	N/A
Yukon	Biologics and Biosimilars	Tildrakizumab	Ilumya™	No	N/A

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://pdf.hres.ca/dpd_pm/00064464.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

↑ Back to list of biologics and biosimilars

SPEVIGO^® (IL 36 Blocker)

How Does It Work?

SPEVIGO (spesolimab for injection) inhibits the inflammatory signaling pathway of interleukin 36 (IL-36), and is indicated for the treatment of flares in adult patients with generalized pustular psoriasis (GPP).

How Is It Used?

Treatment with SPEVIGO (spesolimab for injection) should be initiated by physicians experienced in the management of patients with inflammatory skin diseases.

The recommended dose of SPEVIGO (spesolimab for injection) is a single dose of 900 mg (2 x 450 mg/7.5 ml vials) administered as an intravenous infusion. If flare symptoms persist, an additional 900 mg dose may be administered 1 week after the initial dose.

What Are The Possible Side Effects?

The most common side effects of SPEVIGO (spesolimab for injection) include fatigue/weakness, nausea and vomiting, headache, itching or itchy bumps, a collection of blood under the skin at the infusion site or bruising, and urinary tract infection. To obtain a comprehensive list of all known potential side effects of roflumilast, talk to your doctor or pharmacist.

Any Other Important Considerations?

SPEVIGO (spesolimab for injection) is contraindicated in patients with severe or life-threatening hypersensitivity to this drug or to any ingredients in the formulation, including any non-medicinal ingredients, or components of the container.

What Medications Interact With This Treatment?

No formal drug-drug interaction studies were conducted with SPEVIGO (spesolimab for injection). For a complete list of medications that may interact with SPEVIGO (spesolimab for injection) and to understand how a potential drug interaction should be managed, talk to your doctor or pharmacist.

Province

Class

Generic Name

Drug Name

Psoriasis

Psoriatic Arthritis

More information is available on S/A (special access), L/U (limited use) and Exceptional Drug Status (EDS) at Special Access / Limited Use Designation Drugs.

NIHB stands for non-insured health benefits.

This site is updated regularly; however this information is subject to change. Access may also vary depending on the specific plan. For the most up-to-date information regarding your specific province / territory click here.

Product Monograph

https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=102523

https://pdf.hres.ca/dpd_pm/00070263.PDF

The product monograph is created by Health Canada to summarize the evidence that it reviewed in order to permit this drug to be sold to patients in Canada. It includes information about the drug’s indication (reason for using it), side effects, and any safety warning information. This is used by prescribers, pharmacists, insurance providers and others to use the drug safely. The information can be very detailed and we encourage you to ask your healthcare provider any questions you may have.

This site is updated regularly; however this information is subject to change. For the most up-to-date information regarding product monographs, search here.

Patient Support Program

headstartGO@supportprogram.com

Call toll-free: 1-833-773-4746

MedInfo can be accessed by health care providers for possible inquiries (1-800-263-5103 x84643, zrburmedinfo@boehringer-ingelheim.com).

↑ Back to list of biologics and biosimilars

Last updated May 31, 2024.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Membership

List of Biologic & Biosimilar Drugs

List of Biologics and Biosimilars (Psoriasis)

TNF Blockers

IL17 Blockers

IL12/23 Blockers

IL23 Blockers

IL36 Blocker (generalized pustular psoriasis flares)

List of Biologics and Biosimilars (Psoriatic Arthritis)

TNF Blockers

IL17 Blockers

IL12/23 Blockers

Abatacept

Etanercept (TNF Blocker)

How Does It Work?

How Is It Used?

What Are The Possible Side Effects?

Any Other Important Considerations?

What Medications Interact With This Treatment?

Product Monograph

Adalimumab (TNF Blocker)

How Does It Work?

How Is It Used?

What Are The Possible Side Effects?

Any Other Important Considerations?

What Medications Interact With This Treatment?

Product Monograph

Infliximab (TNF Blocker)

How Does It Work?

How Is It Used?

What Are The Possible Side Effects?

Any Other Important Considerations?

What Medications Interact With This Treatment?

Product Monograph

Certolizumab pegol (TNF Blocker)

How Does It Work?

How Is It Used?

What Are The Possible Side Effects?

Any Other Important Considerations?

What Medications Interact With This Treatment?

Product Monograph

Golimumab (TNF Blocker)

How Does It Work?

How Is It Used?

What Are The Possible Side Effects?

Any Other Important Considerations?

What Medications Interact With This Treatment?

Product Monograph

Ixekizumab (IL17 Blocker)

How Does It Work?

How Is It Used?

What Are The Possible Side Effects?

Any Other Important Considerations?

What Medications Interact With This Treatment?

Product Monograph

Brodalumab (IL17 Blocker)

How Does It Work?

How Is It Used?

What Are The Possible Side Effects?

Any Other Important Considerations?

What Medications Interact With This Treatment?

Product Monograph

Secukinumab (IL17 Blocker)

How Does It Work?

How Is It Used?

What Are The Possible Side Effects?

Any Other Important Considerations?

What Medications Interact With This Treatment?

Product Monograph

Bimekizumab (IL17 Blocker)

How Does It Work?

How Is It Used?

What Are The Possible Side Effects?

Any Other Important Considerations?

What Medications Interact With This Treatment?

Product Monograph

Ustekinumab (IL12/23 Blocker)

How Does It Work?

How Is It Used?

What Are The Possible Side Effects?

SPEVIGO^® (IL 36 Blocker)